Protocol Ledger

NCT07753603 · Phase III · RECRUITING

Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

Interventional Phase III clinical trial protocol NCT07753603 sponsored by Sling Therapeutics in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-04 Enrollment: 130 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07753603
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07753603
Protocol FieldVerified Registry Value
NCT IdentifierNCT07753603
Consolidated Lead SponsorSling Therapeutics
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment130 participants (ESTIMATED)
Registered Start Date2026-08-04
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI